Key result
Rivaroxaban was associated with lower recurrent VTE than LMWH or warfarin, but differing baseline risks (13.5% vs 8.7% very high-risk cancer) and competing risks of death complicate interpretation.
Why the study?
Does rivaroxaban reduce recurrent VTE and major bleeding compared to LMWH or warfarin in newly diagnosed cancer patients with VTE?
Population
Newly diagnosed cancer patients treated for venous thromboembolism during 2013-2015
Comparison
Rivaroxaban vs Low molecular weight heparin (LMWH) or warfarin
Design
Editorial
Authors
Loading...
This editorial cautions against overinterpreting real-world observational data on NOACs for cancer-associated VTE when methodological flaws, such as ignoring competing risks of death, are present.
Does rivaroxaban reduce recurrent VTE and major bleeding compared to LMWH or warfarin in newly diagnosed cancer patients with VTE?
This editorial cautions against overinterpreting real-world observational data on NOACs for cancer-associated VTE when methodological flaws, such as ignoring competing risks of death, are present.
Søgaard et al. (2018) conducted an editorial in cancer-associated venous thromboembolism. Rivaroxaban vs. LMWH or warfarin was evaluated on recurrent VTE and major bleeding. Rivaroxaban was associated with lower recurrent VTE than LMWH or warfarin, but differing baseline risks (13.5% vs 8.7% very high-risk cancer) and competing risks of death complicate interpretation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: